Trinity Biotech (TRIB)
(Real Time Quote from BATS)
$1.24 USD
-0.04 (-3.13%)
Updated Sep 20, 2024 02:14 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TRIB 1.24 -0.04(-3.13%)
Will TRIB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TRIB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRIB
Will Trinity Biotech Stock Gain From Its Latest Patent Process?
Trinity Biotech (TRIB) to Grow in Wearable Biosensor With Buyout
TRIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TRIB
Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer
Trinity Biotech provides update on CGM technology collaboration with Bayer
Trinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology
Trinity Biotech Announces Upcoming AGM
Trinity Biotech Releases 2023 Annual Report